{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"246"},{"groupId":"OG001","value":"237"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"250"},{"groupId":"OG001","value":"239"}],"units":"Participants"}],"description":"An AE was any untoward medical occurrence in a clinical study participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.. TEAE was defined as a newly occurring or worsening AE after the first dose of study treatment and with onset date on or before 30 days after the last dose of study treatment.","groups":[{"description":"Participants with rCC/mCC were administered tisotumab vedotin 2.0 milligram per kilogram (mg/kg) as an intravenous (IV) infusion once every 3 weeks (Q3W).","id":"OG000","title":"Tisotumab Vedotin"},{"description":"Participants with rCC/mCC were treated with investigator's choice of chemotherapy which included either topotecan 1 or 1.25 milligram per meter square \\[mg/m\\^2\\] IV on Days 1 to 5, every 21 days or vinorelbine 30 mg/m\\^2 IV on Days 1 and 8, every 21 days or gemcitabine 1000 mg/m\\^2 IV on Days 1 and 8, every 21 days or irinotecan 100 or 125 mg/m\\^2 IV weekly for 28 days, every 42 days or pemetrexed 500 mg/m\\^2 on Day 1, every 21 days.","id":"OG001","title":"Chemotherapy"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety analysis set included all randomized participants who received at least 1 dose of study treatment (tisotumab vedotin or chemotherapy).","reportingStatus":"POSTED","timeFrame":"From start of treatment up to 30 days after last dose of study treatment (up to 25 months)","title":"Number of Participants With Treatment Emergent Adverse Events (TEAEs)","type":"SECONDARY","unitOfMeasure":"Participants"}